Qiagen (QGEN) AI Stock Analysis

• Market Cap: $9.36B
• Dividend Yield: 2.83%
• Average Volume (3M): 1.15M
• Price to Earnings (P/E): 23.3
• Beta (1Y): 0.64
• Revenue Growth: 5.32%
• EPS Growth: 336.29%
• Country: US
• Employees: 5,700
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.61
• Shares Outstanding: 216,834,000
• 10 Day Avg. Volume: 1,539,521
• 30 Day Avg. Volume: 1,150,355
• PEG Ratio: -1.59
• Price to Book (P/B): 2.78
• Price to Sales (P/S): 5.01
• P/FCF Ratio: 19.58
• Enterprise Value/Market Cap: 1.09
• Enterprise Value/Revenue: 4.92
• Enterprise Value/Gross Profit: 7.80
• Enterprise Value/Ebitda: 12.52
• 1Y Price Target: $49.34
• Price Target Upside: 11.58% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 68 Neutral
• Price Target: $47.00 ▲(6.29% Upside)

Qiagen's overall stock score is driven by strong earnings call performance and strategic growth initiatives. However, technical analysis indicates bearish momentum, and valuation metrics suggest potential overvaluation. Financial performance is solid but tempered by concerns over revenue and cash flow trends.

Positive Factors

Strategic Acquisitions

The acquisition of Parse Biosciences enhances Qiagen's portfolio in the growing AI-driven single-cell market, supporting long-term growth.

Revenue Growth

Consistent revenue growth indicates strong market demand and effective sales strategies, supporting sustained business expansion.

Shareholder Returns

The share repurchase program reflects confidence in future performance and enhances shareholder value through capital return.

Negative Factors

Revenue Growth Slowdown

Slowing revenue growth could indicate market saturation or increased competition, potentially impacting long-term expansion.

Negative Free Cash Flow Growth

Negative free cash flow growth may limit the company's ability to invest in new opportunities and maintain financial flexibility.

Currency and Tariff Headwinds

Currency and tariff challenges can erode profit margins, affecting the company's ability to sustain its financial performance.

Qiagen Business Overview & Revenue Model

Company Description

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

How the Company Makes Money

Qiagen generates revenue primarily through the sale of its molecular testing products and services, which fall into several key categories: sample technologies, assay technologies, and bioinformatics. The company benefits from a diversified revenue model, with substantial income derived from both consumables (such as kits and reagents) and instruments used in laboratories. Additionally, Qiagen has established significant partnerships with various pharmaceutical and biotechnology companies, which can lead to collaborative development of diagnostic tests and expand their market reach. The growing demand for personalized medicine and advancements in genetic testing further contribute to Qiagen's earnings, as they cater to the increasing need for precision diagnostics in healthcare.

Qiagen Financial Statement Overview

Summary

Qiagen demonstrates strong profitability with healthy margins and a stable financial position. However, the slowdown in revenue growth and negative free cash flow growth are concerns that need monitoring.

Income Statement

Qiagen's income statement shows strong profitability with a TTM gross profit margin of 63.14% and a net profit margin of 19.58%. The company has demonstrated consistent revenue growth, with a TTM revenue growth rate of 1.51%. EBIT and EBITDA margins are healthy at 25.53% and 38.73% respectively, indicating efficient operations. However, the revenue growth rate has slowed compared to previous years, which could be a concern if this trend continues.

Balance Sheet

The balance sheet reflects a stable financial position with a debt-to-equity ratio of 0.41, indicating manageable leverage. The return on equity (ROE) is 11.57%, showing effective use of equity to generate profits. The equity ratio is strong, suggesting a solid capital structure. However, the slight increase in total debt over the years warrants monitoring to ensure it remains sustainable.

Cash Flow

Cash flow analysis reveals a slight decline in free cash flow growth at -3.84% TTM, which could impact future investments. The operating cash flow to net income ratio is 0.60, indicating adequate cash generation relative to net income. The free cash flow to net income ratio of 0.74 suggests a reasonable conversion of earnings to cash. Despite these strengths, the negative free cash flow growth rate is a potential risk factor.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.07B	1.98B	1.97B	2.14B	2.25B	1.87B
Gross Profit	1.31B	967.35M	1.23B	1.38B	1.45B	1.23B
EBITDA	814.44M	368.26M	688.55M	779.36M	895.24M	715.80M
Net Income	405.37M	83.59M	341.30M	423.21M	512.60M	359.19M
Balance Sheet
Total Assets	6.55B	5.69B	6.12B	6.29B	6.15B	5.87B
Cash, Cash Equivalents and Short-Term Investments	1.69B	1.15B	1.06B	1.42B	1.07B	715.23M
Total Debt	2.13B	1.42B	1.53B	1.88B	1.96B	1.95B
Total Liabilities	2.90B	2.12B	2.31B	2.82B	3.05B	3.07B
Stockholders Equity	3.65B	3.57B	3.81B	3.47B	3.10B	2.80B
Cash Flow
Free Cash Flow	477.26M	506.38M	296.65M	565.93M	432.47M	188.03M
Operating Cash Flow	657.70M	673.55M	459.45M	715.26M	639.00M	492.27M
Investing Cash Flow	-85.60M	-249.23M	-87.66M	-726.76M	-202.43M	-453.29M
Financing Cash Flow	-189.60M	-422.90M	-433.83M	-125.80M	-150.37M	-74.32M

Qiagen Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 44.22
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QGEN, the sentiment is Negative. The current price of 44.22 is below the 20-day moving average (MA) of 46.65, below the 50-day MA of 46.33, and below the 200-day MA of 44.55, indicating a bearish trend. The MACD of -0.94 indicates Positive momentum. The RSI at 38.63 is Neutral, neither overbought nor oversold. The STOCH value of 16.79 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QGEN.

Qiagen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IDXX	78 Outperform	$56.66B	56.48	64.63%	―	8.39%	21.44%
IQV	77 Outperform	$35.84B	29.25	19.55%	―	3.85%	-4.74%
ILMN	73 Outperform	$18.63B	27.27	31.20%	―	-2.39%	―
TMO	73 Outperform	$216.54B	33.30	13.14%	0.29%	3.22%	8.26%
QGEN	68 Neutral	$9.36B	23.29	11.29%	2.83%	5.32%	336.29%
RVTY	66 Neutral	$10.29B	45.40	3.04%	0.29%	3.37%	-18.80%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Qiagen Corporate Events

QIAGEN Announces Q3 Results, Parse Acquisition, and Share Repurchase

On November 4, 2025, QIAGEN announced its third-quarter financial results, showing a 6% increase in net sales compared to the previous year, and raised its full-year adjusted EPS target to $2.38. The company also revealed plans to acquire Parse Biosciences, expanding its Sample technologies portfolio into the single-cell market, and announced a $500 million synthetic share repurchase to enhance shareholder value. Additionally, CEO Thierry Bernard will step down after a successor is appointed, marking a leadership transition.

Qiagen Reports Strong Asset Growth in Q3 2025

On November 5, 2025, Qiagen N.V. released its quarterly report for the period ending September 30, 2025, prepared under U.S. GAAP. The report highlights a significant increase in total assets, reaching $6.55 billion compared to $5.69 billion at the end of 2024. This growth is attributed to increases in cash and cash equivalents, goodwill, and property, plant, and equipment. The financial results reflect Qiagen’s strengthened market position and operational expansion, which may positively impact stakeholders by enhancing the company’s capacity to invest in innovation and market opportunities.

Qiagen Releases Q2 2025 Financial Report Highlighting Asset Growth

Qiagen N.V. has released its quarterly report for the period ended June 30, 2025, prepared under U.S. GAAP. The report highlights financial performance, including an increase in total assets to $5.82 billion from $5.69 billion at the end of 2024, and a rise in goodwill and intangible assets. These financial results reflect Qiagen’s ongoing efforts to strengthen its market position and operational capabilities, which could have positive implications for stakeholders and the company’s competitive standing in the biotechnology sector.